Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8 Purity ≥99.5% (HPLC) Sitagliptin Phosphate Monohydrate ya Kati
Ugavi Viti Vinavyohusiana vya Sitagliptin Phosphate Monohydrate:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydrate API CAS 654671-77-9
2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydrate ya Kati CAS 486460-21-3
| Jina la Kemikali | Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid |
| Visawe | (R)-Sitagliptin Uchafu wa N-Boc-Asidi |
| Nambari ya CAS | 486460-00-8 |
| Nambari ya CAT | RF-PI1192 |
| Hali ya Hisa | Katika Hisa, Uzalishaji Umeongezeka Hadi Tani |
| Mfumo wa Masi | C15H18F3NO4 |
| Uzito wa Masi | 333.31 |
| Kiwango cha kuyeyuka | 136.0~138.0℃ |
| Chapa | Ruifu Chemical |
| Kipengee | Vipimo |
| Mwonekano | Poda Nyeupe hadi Nyeupe |
| Utambulisho na HPLC | Muda wa Kuhifadhi Sampuli unalingana na Kiwango cha Marejeleo |
| Kupoteza kwa Kukausha | ≤0.50% |
| Majivu yenye Sulphated | ≤0.50% |
| Vyuma Vizito | <20ppm |
| Isoma | ≤0.50% |
| Dutu Zinazohusiana | |
| Uchafu A | ≤0.50% |
| Uchafu Mwingine Wowote | ≤0.50% |
| Jumla ya Uchafu | ≤0.50% |
| Usafi | ≥99.5% (HPLC) |
| Kiwango cha Mtihani | Kiwango cha Biashara |
| Matumizi | Kati ya Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9) |
Kifurushi: Chupa, mfuko wa karatasi ya Alumini, Ngoma ya 25kg/Kadibodi, au kulingana na mahitaji ya mteja.
Hali ya Uhifadhi:Hifadhi kwenye vyombo vilivyofungwa mahali pa baridi na kavu;Kinga kutoka kwa mwanga na unyevu.
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid (CAS: 486460-00-8) ni kati muhimu kwa ajili ya maandalizi ya sitagliptin.Sitagliptinphosphate ni kizuizi cha kwanza cha dipeptidase -IV(DPP-4) kilichoidhinishwa na FDA mwaka wa 2006. Inatumika kwa matibabu ya aina ya pili ya kisukari mellitus.Ina athari ya wazi ya hypoglycemic inapotumiwa peke yake au pamoja na metformin na pioglitazone, na ni salama kuchukua, inavumiliwa vizuri, na athari chache mbaya.Mnamo Agosti 2009, dawa hiyo iliidhinishwa na Umoja wa Ulaya kama dawa ya kwanza kwa matibabu ya aina ya pili ya kisukari.Baada ya 2011, nchi moja baada ya nyingine zimeidhinisha mchanganyiko wa sitagliptin phosphate na vizuizi vya alpha glycosidase au insulini.Sitagliptin fosfati ni kizuizi cha kwanza cha dipeptidyl peptidase-IV kilichoidhinishwa na FDA kutumika kutibu kisukari cha aina ya 2 kufikia sasa, chini ya jina la kibiashara la Januvia.
